Business Wire

NY-THIRD-AVENUE-MGMT

26.2.2024 12:01:30 CET | Business Wire | Press release

Share
Third Avenue Launches Global Value UCITS For Non-U.S. Investors

Third Avenue Management LLC (“Third Avenue”), a New York City-based investment adviser and leading value investing firm, is pleased to announce the upcoming launch of the Third Avenue Global Value Fund (ISIN: IE000K2CIQ63)1. The Fund will run in parallel with Third Avenue’s flagship global value strategy and employ Third Avenue’s unique fundamental, bottom-up, value investing philosophy in publicly traded securities globally.

The global value strategy has been managed for more than three decades and, since its inception in 1990, has provided investors with attractive long-term returns. The Fund will be structured as a sub-fund of Ireland-domiciled UCITS, Gemini Investment Funds (Ireland) Plc2, and is the second UCITS fund offering from Third Avenue along with its highly regarded Third Avenue Real Estate Value Fund (ISIN: IE00B6WFK718).

“We are thrilled to offer the Third Avenue Global Value Fund to qualified non-US investors,” said Portfolio Manager Matthew Fine. “For more than three decades, Third Avenue has delivered attractive results using a unique balance sheet-focused, price-conscious, fundamental value philosophy, an approach that is arguably more uncommon today than at any point in many decades. We also believe it to be an excellent time to broaden the availability of our strategy to a wider investor base, given the rapidly growing investor interest in value strategies as an alternative to growth-oriented and index-based strategies.”

Third Avenue has partnered with Capital Strategies Partners, an independent third-party marketer headquartered in Madrid with a global presence that specializes in identifying talented managers for local distribution.

“We are excited about our partnership with Capital Strategies,” said Erik Kleinbeck, Managing Director and Head of Business Development at Third Avenue. “This relationship allows Third Avenue to focus on our core equity portfolio management expertise while leveraging the reach and scale of Capital Strategies’ 20 years of experience in client acquisition and retention in the asset management industry.”

“We are delighted to extend a warm welcome to Third Avenue as a valued Investment Manager. By launching the Global Value Fund as a UCITS vehicle, we hold firm in our confidence that Third Avenue’s resilient and proven methodology and track record will effectively cater to the needs of our investor base, spanning both institutional and wholesale segments,” said Daniel Rubio, Founder & CEO of Capital Strategies Partners.

“As a business that values our partnerships with Fund Managers in building strong investment propositions for investors, we at GemCap look forward to continuing our collaboration with Third Avenue to launch the Third Avenue Global Value Fund and work with Capital Strategies Partners to deliver this strategy to the broader UCITS fund investor community,” said Stuart Alexander, Director of Gemini Capital Management3.

About Third Avenue Management 
Third Avenue Management LLC is a New York City-based investment adviser founded in 1986 by legendary investor Martin J. Whitman. For more than 35 years, the Firm has consistently pursued a value approach to investing by focusing on the company’s balance sheet, the value of its underlying assets, the discounted price of its securities, and the ability of the enterprise to increase its corporate net worth over time. Today, the Firm is partnered with AMG (NYSE: AMG) and has more than $1.4 billion in assets under management across its five core strategies – Global Value (Nasdaq: TAVFX), U.S. Small-Cap Value (Nasdaq: TASCX), Global Real Estate (Nasdaq: TAREX), International Real Estate (Nasdaq: REIFX), and International Value – which are available to investors through Mutual Funds, UCITS, Separate Accounts, and Sub-Advisory arrangements. For more information visit Third Avenue at www.thirdave.com.

_________________________
1
The launch of the Third Avenue Global Value Fund is subject to final regulatory approval of the Fund, expected around March 1, 2024 
2 Gemini Investment Funds (Ireland) Plc is authorised by the Central Bank of Ireland (C67292) 
3 Gemini Capital Management (Ireland) Ltd is authorised by the Central Bank of Ireland (C155302)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226950474/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye